StocksMedium•19 October 2026•
1 min read
FDA Approves GSK's Jemperli for Rectal Cancer Treatment
Key Facts
1GSK's drug Jemperli received FDA approval for the treatment of rectal cancer.
GSK's drug Jemperli received FDA approval for the treatment of rectal cancer. Investing.com reported that the US Food and Drug Administration granted the approval specifically for treating rectal cancer patients following clinical data that demonstrated the drug's efficacy.
The approval marks a significant milestone for GSK's revenue outlook by expanding its oncology portfolio. The regulatory milestone supports the company's long-term growth strategy in the healthcare sector.